Biotech entity
Every one of those 1 sits in a single category, pharma. Galleri is most often covered alongside Bob Ragusa, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Galleri, all published on March 22, 2026.
Last mentioned: Mar 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Galleri is most often covered alongside Bob Ragusa, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Galleri, all published on March 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Galleri. Shared-story counts are live from our verified record — not editorial picks.
Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Galleri is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
